Drugmaker ‘Pay for Delay’ Accords Questioned by Top Court

U.S. Supreme Court justices suggested they will open drugmakers to suits over so-called pay-for-delay agreements, hinting at a ruling that would rewrite the rules governing the release of generic medicines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.